Cyclooxygenase-2 in human non-small cell lung cancer

Hsin Yuan Fang, T. S. Lin, J. P. Lin, Yu-Chung Wu, K. C. Chow, L. S. Wang

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)


Aim: Recent studies report that the expression of cyclooxygenase (COX) in non-small cell lung cancer (NSCLC) is increased, especially in adenocarcinoma. Platelet activating factor (PAF), n-sodium butyrate (n-BT), and phorbol myristate acetate (PMA) are important mediators of the inflammatory process. Method: Expression of COX-2 in 67 stage 1 NSCLC paraffin-embedded tumor samples was determined by immunohistochemistry (IHC). Four NSCL cell lines were incubated and stimulated by PAF, n-BT and PMA for 48 h. Expression of COX-2 was determined by IHC, immunoblotting, and reverse transcription-polymerase chain reaction (RT-PCR). Result: IHC showed increasing immunoreactivity in 35 of 67 (52%) in stage 1 NSCLC, 31 of 53 (59%) in adenocarcinoma and 13 of 15 (87%) in bronchoalveolar cell carcinoma, but only 2 of 12 (17%) in epidermoid carcinoma. The COX-2 expression in NSCLC cells was 75% (3/4) and the COX-1 expression in NSCLC cells was 100% (4/4). After stimulation with PMA, n-BT, PAF and n-BT + PAF, the COX-2 expression in NSCLC cells was significantly increased in all cell lines. Conclusions: The expression of COX-2 in NSCLC cells is high and was up-regulated by PMA, n-BT and PAF. We consider that COX-2 inhibitors will play an important role in the therapy of NSCLC.

Original languageEnglish
Pages (from-to)171-177
Number of pages7
JournalEuropean Journal of Surgical Oncology
Issue number2
Publication statusPublished - Mar 2003
Externally publishedYes


  • Cyclooxygenase
  • Lung cancer
  • Prostaglandin

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Cyclooxygenase-2 in human non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this